文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性玻璃体腔注射阿柏西普或布西珠单抗后全身血管内皮生长因子水平的变化

CHANGES IN SYSTEMIC LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER INTRAVITREAL INJECTION OF AFLIBERCEPT OR BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
PubMed 文献 · Retina · 2022-01-01

这项前瞻性干预性病例系列研究纳入每组30例新生血管性年龄相关性黄斑变性患者,分别玻璃体腔注射布西珠单抗(6.0 mg/50 µL)或阿柏西普(2.0 mg/50 µL),并以30名健康人作对照,比较首次注射后7天和28天全身VEGF-A水平变化。布西珠单抗组VEGF-A至28天持续降低,阿柏西普组第7天降低但第28天回到基线,两组第28天差异有统计学意义(P < 0.001)。

要点

  • 布西珠单抗组全身VEGF-A中位数从基线10.8 pg/mL降至第7天8.0 pg/mL(P = 0.0254)和第28天8.0 pg/mL(P < 0.001)。
  • 阿柏西普组从基线12.0 pg/mL降至第7天8.0 pg/mL(P < 0.001),第28天回到12.5 pg/mL(P = 0.120)。
  • 两组第28天全身VEGF-A水平差异有统计学意义(P < 0.001)。

核心结论

  • 玻璃体腔注射布西珠单抗导致全身VEGF-A水平持续降低至治疗后28天,作者认为这引发对其安全性和长期效应的关注。

研究设计与样本

  • 前瞻性干预性病例系列研究,布西珠单抗组和阿柏西普组各30例患者,另设30名健康对照。
  • 布西珠单抗剂量为6.0 mg/50 µL,阿柏西普剂量为2.0 mg/50 µL,均玻璃体腔注射。
  • 于基线及首次注射后7天和28天采血,采用酶联免疫吸附试验测定全身VEGF-A水平。

主要发现

  • 布西珠单抗组、阿柏西普组和对照组基线全身VEGF-A中位数分别为10.8(8.0-13.2)、12.0(8.0-18.5)和10.0(8.0-15.1)pg/mL(P = 0.315)。
  • 布西珠单抗组第7天降至8.0(8.0-11.5)pg/mL(P = 0.0254),第28天降至8.0(8.0-8.0)pg/mL(P < 0.001)。
  • 阿柏西普组第7天降至8.0(8.0-8.0)pg/mL(P < 0.001),第28天回到12.5(8.5-14.6)pg/mL(P = 0.120)。
  • 两组第28天全身VEGF-A水平差异有统计学意义(P < 0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To analyze and compare the effects of intravitreal brolucizumab versus aflibercept on systemic vascular endothelial growth factor (VEGF)-A levels in patients with neovascular age-related macular degeneration. METHODS: In this prospective interventional case series study, brolucizumab (6.0 mg/50 µL) or aflibercept (2.0 mg/50 µL) was injected intravitreally in 30 patients each. Blood samples were drawn at baseline and 7 days and 28 days after the first injection. Systemic VEGF-A levels were measured using enzyme-linked immunosorbent assay. Thirty healthy individuals served as controls. RESULTS: The median baseline systemic VEGF-A levels in the brolucizumab, aflibercept, and control groups were 10.8 (8.0-13.2), 12.0 (8.0-18.5), and 10.0 (8.0-15.1) pg/mL, respectively (P = 0.315). In the brolucizumab group, VEGF-A levels significantly decreased to 8.0 (8.0-11.5) pg/mL on Day 7 (P = 0.0254) and to 8.0 (8.0-8.0) pg/mL on Day 28 (P < 0.001). In the aflibercept group, VEGF-A levels significantly decreased to 8.0 (8.0-8.0) pg/mL on Day 7 (P < 0.001) but returned to the baseline level, 12.5 (8.5-14.6) pg/mL, on Day 28 (P = 0.120). Vascular endothelial growth factor-A levels were significantly different between the treatment groups after 28 days (P < 0.001). CONCLUSION: Intravitreal brolucizumab resulted in a sustained reduction of systemic VEGF-A levels until 28 days posttreatment, which raises concerns regarding its safety and long-term effects.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Angermann R, Huber AL, Nowosielski Y, et al. CHANGES IN SYSTEMIC LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER INTRAVITREAL INJECTION OF AFLIBERCEPT OR BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2022. PMID: 34731094. doi:10.1097/IAE.0000000000003344

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。